According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “
A number of other analysts have also recently issued reports on the company. HC Wainwright set a $21.00 price objective on Stealth BioTherapeutics and gave the stock a buy rating in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on Stealth BioTherapeutics in a report on Friday, September 27th. They set an overweight rating and a $18.00 price objective on the stock. Jefferies Financial Group set a $9.00 price objective on Stealth BioTherapeutics and gave the stock a hold rating in a report on Tuesday, October 15th. Finally, Nomura set a $28.00 price objective on Stealth BioTherapeutics and gave the stock a buy rating in a report on Friday, October 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of $21.86.
NASDAQ MITO traded up $0.91 on Tuesday, reaching $8.64. The company had a trading volume of 50,400 shares, compared to its average volume of 24,505. The company’s fifty day moving average is $6.54 and its 200 day moving average is $10.35. The stock has a market capitalization of $250.11 million and a P/E ratio of -6.13. The company has a quick ratio of 2.13, a current ratio of 2.13 and a debt-to-equity ratio of 0.54. Stealth BioTherapeutics has a 52-week low of $4.97 and a 52-week high of $20.99.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). On average, research analysts expect that Stealth BioTherapeutics will post -0.2 EPS for the current year.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Story: What are the benefits of investing in REITs?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.